The popularity of Sildenafil initially drove a surge for pharma, however recent changes present a complicated picture for shareholders. Off-patent competitors are reducing profits, and continued litigation add further https://cormacfgrw199333.ampedpages.com/the-blue-pill-and-pharma-a-precarious-investment-68189769